Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: Allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans

Cancer Chemotherapy and Pharmacology

Volumn 39, Issue 3, 1996, Pages 233-238

  Khor, Soo Peang ^a   Amyx, Herb ^a   Davis, Stephen T ^a   Nelson, Donald ^a   Baccanari, David P ^a   Spector, Thomas ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

5 Ethynyluracil; 5 Fluorouracil; Allometric scaling; Dehydrogenase inactivation; Dihydropyrimidine; Pharmacokinetics

Indexed keywords

5 ETHYNYLURACIL; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CONTINUOUS INFUSION; DOG; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG SAFETY; DRUG TOLERANCE; DRUG TOXICITY; ENZYME INHIBITION; GENETIC PREDISPOSITION; HUMAN; INFORMATION PROCESSING; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAXIMUM PERMISSIBLE DOSE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SPECIES DIFFERENCE; TECHNIQUE; TOXICOKINETICS;

EID: 0031060493     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050566     Document Type: Article

References (26)

1. Baccanari DP, Davis ST, Knick VC, Spector T (1993) 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. Proc Natl Acad Sci USA 90: 11064
2. Boxenbaum H (1982) Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10: 201
3. Caballero GA, Ausman RK, Quebbeman EJ (1985) Long-term, ambulatory, continuous iv infusion of 5-FU for the treatment of advanced adenocarcinomas. Cancer Treat Rep 69: 13-15
4. Chabner BA, Myer CE (1989) Clinical pharmacology of cancer chemotherapy. In: De Vita V, Hellman S, Rosenberg S (eds), Principles and practice of oncology, Lippincott, Philadelphia, pp 344-345
5. Collins JM, Dedrick RL, King FG, Speyer JL, Myers CE (1980) Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal roules. Clin Pharmacol Ther 28: 235
6. Czejka MJ, Jager W, Schuller J, Fogl U, Weiss C, Schernthaner G (1993) Clinical pharmacokinetics of 5-fluorouracil. Influence of the biomodulating agents interferon, dipyridamole and folinic acid alone and in combination. Arzneimittelforschung 43: 387
7. Daher GC, Harris BE, Diasio RB (1990) Metabolism of pyrimidine analogues and their nucleosides. Pharmacol Ther 48: 189
8. Diasio RB, Harris BE (1989) Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16: 215
9. Diasio RB, Beavers TL, Carpenter JT (1988) Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 81: 47
10. Dorr RT, Von Hoff DD (1994) 5-Fluorouracil. In: Dorr RT, Von Hoff DD (eds) Cancer chemotherapy handbook, 2nd edn. Appleton & Lange, Norwalk, pp 507-508
11. Fleming RA, Milano G, Thyss A, Etienne MC, Renee N, Schneider M, Demard F (1992) Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 52: 2899
12. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Swarbrick J, (ed) Marcel Dekker, New York
13. Groeningen CJ van, Pinedo HM, Heddes J, Kok RM, Jong AP de, Wattel E, Peters GJ, Lankelma J (1988) Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res 48: 6956
14. Hansen RM (1991) 5-Fluorouracil by protracted venous infusion: a review of recent clinical studies. Cancer Invest 9: 637
15. Harris BE, Song R, Soong SJ, Diasio RB (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50: 197
16. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47: 2203
17. Holt JP, Rhode EA (1976) Similarity of renal glomerular hemodynamics in mammals. Am Heart J 92: 465
18. Keizer HJ, De Bruijn EA, Tjaden UR, De Clercq E (1994) Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2′-deoxyuridine. J Cancer Res Clin Oncol 120: 545
19. Khor SP, Lucas S, Schilsky R, Burris H, Von Hoff DD, Zhang R, Spector T (1995) A Phase I/pharmacokinetic study of 5-ethynyluracil plus 5-fluorouracil in cancer patients with solid tumors. Proc Am Assoc Cancer Res 36: 241
20. Lokich J, Bothe A, Fine N, Perri J (1981) Phase I study of protracted venous infusion of 5-fluorouracil. Cancer 48: 2565
21. Metzler CM, Elfring GL, McEwen AJ (1974) A package of computer programs for pharmacokinetic modeling. Biometrics 30: 123-456
22. Porter DJ, Chestnut WG, Merrill BM, Spector T (1992) Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil. J Biol Chem 267: 5236
23. Santini J, Milano G, Thyss A, Renee N, Viens P, Ayela P, Schneider M, Demard F (1989) 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 59: 287
24. Spector T, Harrington JA, Porter DJ (1993) 5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo. Biochem Pharmacol 46: 2243
25. Spicer DV, Ardalan B, Daniels JR, Silberman H, Johnson K (1988) Reevaluation of the maximum tolerated dose of continuous venous infusion of 5-fluorouracil with pharmacokinetics. Cancer Res 48: 459
26. Yoshida T, Araki E, Iigo M, Fujii T, Yoshino M, Shimada Y, Saito D, Tajiri H, Yamaguchi H, Yoshida S, et al (1990) Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer. Cancer Chemother Pharmacol 26: 352